A Phase II Study of Low-Dose Interleukin-2 by Subcutaneous Injection in Combination With Antiretroviral Therapy Versus Antiretroviral Therapy Alone in Patients With HIV-1 Infection and at Least 3 Months Stable Antiretroviral Therapy

NCT00000820 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

104

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

DRUG: Aldesleukin

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)